FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3159736356> ?p ?o ?g. }

• W3159736356 endingPage "S75" @default.
• W3159736356 startingPage "S75" @default.
• W3159736356 abstract "While aspartate aminotransferase-lymphocyte ratio (ALRI) has been found to be prognostic in metastatic colorectal (mCRC) patients undergoing systemic therapy, little data is available regarding its utility in patients undergoing radioembolization. The purpose of this study was to evaluate the usefulness of ALRI in predicting radiologic response and overall survival (OS) following radioembolization for mCRC patients. Between January 1, 2014, and December 31, 2019, a total of 42 patients who underwent radioembolization for the treatment of mCRC were reviewed. The patient’s electronic medical records were evaluated for pre and post procedural laboratory values as well as radiologic response according to the European Association for the Study of the Liver (EASL) criteria. Overall radiologic response (ORR) was defined as those who showed a partial or complete response. Survival was measured from the initial radioembolization to time of death. Patients were separated into cohorts utilizing an ALRI of 65. The cohort consisted of 50% (21/42) women and 50% (21/42) men with an average age of 59.1 ± 13.8 years. The average pretreatment ALRI was 65.2 ± 68.9. When comparing those who had an ORR to those who did not there was not a significant difference in ALRI between the two groups (63.3 ± 83.1 vs 51.7 ± 47.9, P = 0.32). While the OS was longer for those with an ALRI < 65 (1.31 ± 1.46 years) as compared to those with an ALRI ≥65 (0.85 ± 0.55 years) it was not significantly so (P = 0.09). Of those patients with both pre and post TACE ALRI values, those that demonstrated a decrease in ALRI did not differ in OS from those who had an increase in ALRI (1.21 ± 1.24 vs 0.55 ± 0.18 years, P = 0.16). However, those who had an increase in ALRI following radioembolization were more likely to have an ORR as compared to those with a decrease in ALRI (13/21 (61.9%) vs 0/5 (0%), P = 0.05). While ALRI did not seem to predict OS in mCRC patients, an increase in ALRI, an indirect measure of systemic inflammation, corresponded to improved radiologic responses. This is an interesting and unexpected finding." @default.
• W3159736356 created "2021-05-10" @default.
• W3159736356 creator A5009990060 @default.
• W3159736356 creator A5017499240 @default.
• W3159736356 creator A5042261688 @default.
• W3159736356 creator A5044107299 @default.
• W3159736356 creator A5066806993 @default.
• W3159736356 creator A5067063023 @default.
• W3159736356 creator A5075628539 @default.
• W3159736356 creator A5078001562 @default.
• W3159736356 creator A5079348540 @default.
• W3159736356 creator A5085188981 @default.
• W3159736356 date "2021-05-01" @default.
• W3159736356 modified "2023-09-26" @default.
• W3159736356 title "Abstract No. 169 Aspartate aminotransferase-lymphocyte ratio: predictive value in metastatic colorectal patients undergoing radioembolization" @default.
• W3159736356 doi "https://doi.org/10.1016/j.jvir.2021.03.175" @default.
• W3159736356 hasPublicationYear "2021" @default.
• W3159736356 type Work @default.
• W3159736356 sameAs 3159736356 @default.
• W3159736356 citedByCount "0" @default.
• W3159736356 crossrefType "journal-article" @default.
• W3159736356 hasAuthorship W3159736356A5009990060 @default.
• W3159736356 hasAuthorship W3159736356A5017499240 @default.
• W3159736356 hasAuthorship W3159736356A5042261688 @default.
• W3159736356 hasAuthorship W3159736356A5044107299 @default.
• W3159736356 hasAuthorship W3159736356A5066806993 @default.
• W3159736356 hasAuthorship W3159736356A5067063023 @default.
• W3159736356 hasAuthorship W3159736356A5075628539 @default.
• W3159736356 hasAuthorship W3159736356A5078001562 @default.
• W3159736356 hasAuthorship W3159736356A5079348540 @default.
• W3159736356 hasAuthorship W3159736356A5085188981 @default.
• W3159736356 hasBestOaLocation W31597363561 @default.
• W3159736356 hasConcept C121608353 @default.
• W3159736356 hasConcept C126322002 @default.
• W3159736356 hasConcept C141071460 @default.
• W3159736356 hasConcept C167135981 @default.
• W3159736356 hasConcept C2777761686 @default.
• W3159736356 hasConcept C526805850 @default.
• W3159736356 hasConcept C71924100 @default.
• W3159736356 hasConcept C72563966 @default.
• W3159736356 hasConcept C90924648 @default.
• W3159736356 hasConceptScore W3159736356C121608353 @default.
• W3159736356 hasConceptScore W3159736356C126322002 @default.
• W3159736356 hasConceptScore W3159736356C141071460 @default.
• W3159736356 hasConceptScore W3159736356C167135981 @default.
• W3159736356 hasConceptScore W3159736356C2777761686 @default.
• W3159736356 hasConceptScore W3159736356C526805850 @default.
• W3159736356 hasConceptScore W3159736356C71924100 @default.
• W3159736356 hasConceptScore W3159736356C72563966 @default.
• W3159736356 hasConceptScore W3159736356C90924648 @default.
• W3159736356 hasIssue "5" @default.
• W3159736356 hasLocation W31597363561 @default.
• W3159736356 hasOpenAccess W3159736356 @default.
• W3159736356 hasPrimaryLocation W31597363561 @default.
• W3159736356 hasRelatedWork W2002120878 @default.
• W3159736356 hasRelatedWork W2003938723 @default.
• W3159736356 hasRelatedWork W2047967234 @default.
• W3159736356 hasRelatedWork W2118496982 @default.
• W3159736356 hasRelatedWork W2364998975 @default.
• W3159736356 hasRelatedWork W2439875401 @default.
• W3159736356 hasRelatedWork W2603773853 @default.
• W3159736356 hasRelatedWork W4238867864 @default.
• W3159736356 hasRelatedWork W2519357708 @default.
• W3159736356 hasRelatedWork W2525756941 @default.
• W3159736356 hasVolume "32" @default.
• W3159736356 isParatext "false" @default.
• W3159736356 isRetracted "false" @default.
• W3159736356 magId "3159736356" @default.
• W3159736356 workType "article" @default.